Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733396 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP2D6LMNAPOLBL3MBTL1 | |
| SCHEMBL12788948 | 0.94 | CYP3A4 (0.45) | CYP3A4CYP2D6LMNAPOLBL3MBTL1 | |
| SCHEMBL15120134 | 0.94 | CYP3A4 (0.45) | CYP3A4CYP2D6LMNAPOLBL3MBTL1 | |
| SCHEMBL21393880 | 0.90 | LMNA (0.41) | CYP3A4CYP2D6LMNAPOLBL3MBTL1 | |
| SCHEMBL15373850 | 0.90 | LMNA (0.41) | CYP3A4CYP2D6LMNAPOLBL3MBTL1 | |
| SCHEMBL12733414 | 0.82 | POLB (0.58) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| SCHEMBL12733429 | 0.82 | CYP3A4 (0.46) | CYP3A4CYP2D6LMNAPOLBSMN1; SMN2 | |
| SCHEMBL12733413 | 0.82 | CYP3A4 (0.46) | CYP3A4CYP2D6LMNAPOLBSMN1; SMN2 | |
| SCHEMBL12733464 | 0.82 | CYP3A4 (0.46) | CYP3A4CYP2D6LMNAPOLBSMN1; SMN2 | |
| SCHEMBL12733469 | 0.82 | CYP3A4 (0.46) | CYP3A4CYP2D6LMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNK3 | CYP3A4 465/4885CYP2D6 670/4885LMNA 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.